News

Overpriced medicines/ Te dure medicijnen

7/8/2019

Somo and Wemos react to minister Bruin’s answers to report ‘Overpriced’

The report ‘Overpriced’, which we published together with partner organisation SOMO in May, shows how Dutch tax money is used for the development of new medicines in the Netherlands. Read more

News

1/7/2019

Wemos in EenVandaag: price hike of medicine is abuse of monopoly position of pharma company

The sudden price hike of the medicine Priadel constitutes an abuse of the monopoly position of the pharmaceutical company Essential Pharma. Global health advocate Ella Weggen states this in the programme EenVandaag. Read more

News

28/6/2019

Interactive overview of the highlights of our work

You may have seen them before: the highlights of our work in 2018. But now, we want to share these with you in a clear, fresh new way. Read more

News

26/6/2019

A global action plan for SDG3

In 2018, the governments of Ghana, Germany and Norway requested the World Health Organization (WHO) to take the lead in an initiative to improve the coordination of international cooperation in the health sector. Read more

News

25/6/2019

Wemos’ voting advice in response to recent debate on medicines policy

Members of the Dutch Parliaments’ committee on Health, Welfare and Sport had a debate on medicines policy in The Netherlands. Read more

Map of the Netherlands / Kaart van Nederland

News

17/5/2019

Our report praised as ‘inspiring’ in Dutch SDGs report

In the third edition of the Dutch Sustainable Development Goals (SDGs) report, published this month, our Malawi country report was mentioned as one “inspiring example” of how the SDGs are taking shape by civil society. Read more

News

17/5/2019

An evening in de Rode Hoed about big pharma, concerns and hope

“A collective stranglehold”. This is how the debate moderator Martijn de Greve described the current pharmaceutical system during last night’s debate ‘Pharma’s Other Futures’ in the Rode Hoed. Read more

News

10/5/2019

Overpriced drugs developed with tax money

Overpriced – Drugs developed with Dutch public funding, a report published today jointly by The Centre for Research on Multinational Corporations (SOMO) and Wemos, examines the extent of Dutch public funding of drug development, through donations, loans and/or investments. Read more

News

8/5/2019

This is how the EU & Dutch government can achieve equal access to medicines

Why are (some) medicines so expensive? How are medicines developed in the Netherlands, and how does this system contribute to unequal access to medicines? Read more